Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The mature form of Complement C5 is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. Each α and β chain has a calculated MW of 73.5 kDa (β chain) and 114.6 kDa (α chain). The protein migrates as 66 kDa (β chain) and 100 kDa (α chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Mouse Complement C5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Mouse Complement C5, His Tag (Cat. No. CO5-M52H4) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-13 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Avacincaptad pegol | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Macular Degeneration; Geographic Atrophy | Iveric Bio Inc, Astellas Pharma Inc | 2023-08-04 | Polypoidal choroidal vasculopathy; Wet Macular Degeneration; Geographic Atrophy; Macular Degeneration | Details |
Zilucoplan Sodium | RA-101495-SC; RA-101495; ZLP-AI | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis | Details |
Crovalimab | RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell | Details |
Ravulizumab | ALXN-1210; ALXN-1810 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Respiratory Distress Syndrome, Adult; Amyotrophic Lateral Sclerosis; Acute Lung Injury; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Myasthenia Gravis; Thrombotic Microangiopathies; Heart Diseases; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Dermatomyositis | Details |
Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Neuromyelitis Optica; Macular Degeneration; Kidney Failure, Chronic; Diabetes Mellitus; Urea Cycle Disorders, Inborn; Thrombocytopenia; Guillain-Barre Syndrome; Asthma; Glomerulonephritis, Membranoproliferative; Nasopharyngeal Carcinoma; Parturition; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; Rejection of renal transplantation; End Stage Liver Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome | Details |
Pozelimab | REGN-3918 | Approved | Regeneron Pharmaceuticals Inc | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details |
Eculizumab biosimilar (Amgen) | ABP-959 | Approved | Amgen Inc | BKEMV | United States | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Amgen Inc | 2024-05-28 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; AMT-904; SB12 | Approved | Samsung Bioepis Co Ltd | Epysqli, EPYSQLI | EU | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Samsung Bioepis Nl Bv | 2023-05-26 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | BIOCAD JSC | Hemoglobinuria, Paroxysmal | Details |
Cemdisiran | ALN-CC5; AD-62643; ALN-62643; L96 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Myositis; Atypical Hemolytic Uremic Syndrome; Myositis, Inclusion Body; Geographic Atrophy; Macular Degeneration | Details |
Nomacopan | EV-576; rEV-576; rVA576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Geographic Atrophy; Keratoconjunctivitis | Details |
Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Novartis Pharma Ag, Morphosys Ag | Rejection of renal transplantation; Uveitis, Intermediate; Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Uveitis, Posterior; Panuveitis; Macular Degeneration | Details |
KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
LP-005 | RX-001; LP-005 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Myasthenia Gravis; Peripheral Nervous System Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Amyotrophic Lateral Sclerosis | Details |
Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
RLYB-116 | RLYB-116 | Phase 1 Clinical | Rallybio Llc | Hematologic Diseases; Autoimmune Diseases; Immune System Diseases; Inflammation | Details |
NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
EA-5 | EA5; EA-5 | Phase 1 Clinical | Shanghai Lanyi Pharmaceutical Technology Co Ltd | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases | Details |
eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
This web search service is supported by Google Inc.